非离子型双体对比剂在冠状动脉介入治疗中应用的安全性观察

Safety of isosomolar nonionic dimmer during percutaneous coronary intervention

目的评估非离子型双体等渗对比剂(碘克沙醇)在冠状动脉病变介入治疗(PCI)中应用的安全性。方法285例患者因心绞痛入院行PCI分为两组:非离子型双体对比剂(碘克沙醇组)120例和单体对比剂(碘帕醇组)165例。比较两组的一般情况、PCI前后肾功能变化及对比剂肾病发生率。结果PCI后24h碘克沙醇组血清肌酐升高值显著低于碘帕醇组,分别为(2.55±17.7)mmol/L和(14.39±10.6mmol/L,P<0.01),但两组的对比剂肾病发生率无显著差异,分别为11.7%和19.4%(P>0.05)。结论PCI时应用非离子型双体对比剂安全可靠,且较非离子型单体对比剂显著降低血清肌酐升高幅度,但并不能减低对比剂肾病的发生率。

Objective To assess the safety of isosmolar nonionic dimer iodixanol during percutaneous coronary intervention （PCI）. Methods 285 patients with stable or unstable angina were divided into two groups： isosmolar nonionic dimer iodixanol was used in 120 eases （group Ⅰ）, and low-osmolar nonionic monomer iopamidol was applied to 165 cases （group Ⅱ ）. Baseline clinical characteristics, renal function, occurrence of contrast-induced nephropathy （CIN） during hospitalization were recorded and compared between the two groups. Results The increase of serum creatinine was significantly lower in group Ⅰ than that in group Ⅱ , （2.55 ± 17.7）mmol/L vs （14,39 ± 10.6）mmol/L, （P 〈 0.01）. The incidences of CIN showed no significant difference between the two groups （11.7% vs 19.4% ,P 〉 0.05）. Conclusion The application of isosmolar nonionic dimer iodixanol during PCI is safe with slight increase of serum creatinine level and equal incidences of CIN in comparing with iopamidol.